Mortality in SLE patients compared with population controls in Finland in years 2000–2015

Author:

Elfving Pia1ORCID,Kariniemi Simo12,Kautiainen Hannu34,Virta Lauri J5,Kaipiainen-Seppänen Oili1,Puolakka Kari6

Affiliation:

1. Department of Medicine, Kuopio University Hospital

2. School of Medicine, University of Eastern Finland

3. Unit of Primary Health Care, Kuopio University Hospital, Kuopio

4. Folkhälsan, Research Center, Helsinki

5. Research Department, Social Insurance Institution, Turku

6. Department of Medicine, South Karelia Central Hospital, Lappeenranta, Finland

Abstract

Abstract Objective To estimate the risk of mortality in the Finnish incident SLE cohort in a 16-year period compared with the general population. Methods Adults with new-onset SLE between 1 January 2000 and 31 December 2014 identified from the national drug reimbursement register and their individually matched controls from the Population Register Centre were followed up until death or 31 December 2015. Data on deaths were retrieved from the national causes of death register. Comorbidities and education were obtained by linkage to the other national registries. Results A total of 1006 patients with incident SLE and 3005 population controls were found (mean follow-up 8.6 years). Of these, 98 SLE patients subsequently died. Their 5 -, 10-, and 15-year survival rates were 95.0% (95% CI: 93.3, 96.2), 88.8% (86.2, 91.0), and 82.1% (77.6, 85.8), respectively. Crude hazard ratio (HR) was 1.61 (95% CI: 1.26, 2.06), adjusted for education level was almost the same 1.61 (95% CI: 1.26, 2.05). After adjustment for comorbidities and education at baseline, the difference in mortality disappeared: HR 1.14 (95% CI: 0.88, 1.48). The leading causes of death were cardiovascular diseases (CVDs) (33%), malignancies (27%) and neurological diseases (10%). Subhazard ratio for CVD deaths was 1.28 (95% CI: 0.85, 1.93), adjusted for comorbidities and education 0.88 (95% CI: 0.56, 1.39). Conclusions These results suggest that the increased mortality in SLE patients is highly associated with comorbidities present at diagnosis. This underlines the importance to screen and treat comorbidities and disease actively without delays.

Funder

Finnish Cultural Foundation, North Savo Regional Fund

Publisher

Oxford University Press (OUP)

Subject

Pharmacology (medical),Rheumatology

Reference39 articles.

1. Mortality in systemic lupus erythematosus;Bernatsky;Arthritis Rheum,2006

2. Excess atherosclerosis in systemic lupus erythematosus,—a matter of renal involvement: case control study of 281 SLE patients and 281 individually matched population controls;Gustafsson;PLoS One,2017

3. Evaluation of mortality, disease activity, treatment, clinical and immunological features of adult and late onset systemic lupus erythematosus;Cartella;Autoimmunity,2013

4. The risk of cardiovascular mortality in systemic lupus erythematosus and lupus nephritis: a Danish nationwide population-based cohort study;Hermansen;Rheumatology,2017

5. Infection and lupus: which causes which?;Doaty;Curr Rheumatol Rep,2016

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3